Concord Biotech Limited (NSE:CONCORDBIO) — Market Cap & Net Worth
Market Cap & Net Worth: Concord Biotech Limited (CONCORDBIO)
Concord Biotech Limited (NSE:CONCORDBIO) has a market capitalization of $1.60 Billion (Rs147.99 Billion) as of August 4, 2026. Listed on the NSE stock exchange, this India-based company holds position #6879 globally and #335 in its home market, demonstrating a 13.30% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Concord Biotech Limited's stock price Rs1414.60 by its total outstanding shares 104616204 (104.62 Million). See CONCORDBIO capital expenditure intensity to understand how much of operating cash flow is reinvested back into capital assets.
Concord Biotech Limited Market Cap History: 2023 to 2026
Concord Biotech Limited's market capitalization history from 2023 to 2026. Data shows growth from $1.66 Billion to $1.60 Billion (14.90% CAGR).
Index Memberships
Concord Biotech Limited is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY 500
NIFTY500
|
$3.21 Trillion | 0.05% | #286 of 500 |
|
NIFTY SMALLCAP 250
NISM250
|
$396.83 Billion | 0.40% | #101 of 250 |
Weight: Concord Biotech Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Concord Biotech Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Concord Biotech Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.13x
Concord Biotech Limited's market cap is 0.13 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.41x
Concord Biotech Limited's market cap is 0.41 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $1.66 Billion | $8.53 Billion | $2.40 Billion | 0.19x | 0.69x |
| 2024 | $2.50 Billion | $10.17 Billion | $3.08 Billion | 0.25x | 0.81x |
| 2025 | $1.52 Billion | $12.00 Billion | $3.72 Billion | 0.13x | 0.41x |
Competitor Companies of CONCORDBIO by Market Capitalization
Companies near Concord Biotech Limited in the global market cap rankings as of August 4, 2026.
Key companies related to Concord Biotech Limited by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #564 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $470.72 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $759.24 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €722.20 |
| #564 | UCB SA | BR:UCB | $47.34 Billion | €221.40 |
Concord Biotech Limited Historical Marketcap From 2023 to 2026
Between 2023 and today, Concord Biotech Limited's market cap moved from $1.66 Billion to $ 1.60 Billion, with a yearly change of 14.90%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs1.60 Billion | +5.13% |
| 2025 | Rs1.52 Billion | -39.13% |
| 2024 | Rs2.50 Billion | +51.05% |
| 2023 | Rs1.66 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of Concord Biotech Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.60 Billion USD |
| MoneyControl | $1.60 Billion USD |
| MarketWatch | $1.60 Billion USD |
| marketcap.company | $1.60 Billion USD |
| Reuters | $1.60 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Concord Biotech Limited
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenola… Read more